Iyul: 2021: Breyanzi (Lisocabtagene maraleucel; liso-cel), yangi CD19-yo'naltirilgan kimerik antigen retseptorlari (CAR) T hujayralarini davolash tomonidan ishlab chiqilgan Bristol Mayers Squibb (BMS), AQSh oziq-ovqat va farmatsevtika idorasi (USFDA) tomonidan tasdiqlangan.
CAR-T hujayra terapiyasi saraton hujayralarini tanib olish va yo'q qilish uchun odamning T hujayralarini o'zgartirish orqali ishlaydigan immunoterapiyaning bir turi.
Breyanzi, Bristol Myers Squibb (BMS) tomonidan ishlab chiqilgan CD19-yo'naltirilgan ximerik antigen retseptorlari (CAR) T-hujayralarini davolashning yangi usuli, AQSh tomonidan tasdiqlangan. AQSh oziq-ovqat va dorilar boshqarmasi (USFDA) (Lisocabtagene maraleucel; liso-cel).
Bundan tashqari: Hindistonda CAR T-Cell terapiyasi
Ikki yoki undan ortiq bosqichli tizimli terapiyadan so'ng relapsli yoki refrakter (R / R) katta B-hujayrali limfoma (LBCL) bo'lgan katta yoshli bemorlar yangi dori bilan davolanadilar. CAR T hujayra terapiyasi. Birlamchi mediastinal katta B-hujayrali limfoma, yuqori darajadagi B-hujayrali limfoma, follikulyar limfoma 3B va boshqa tavsiflanmagan DLBCL kabi bir necha turdagi LBCL mavjud bo'lib, ular indolent limfomadan ham rivojlanishi mumkin.
DLBCL saratoni Hodgkin bo'lmagan limfoma (NHL) ning eng tez-tez uchraydigan turi bo'lib, bu agressiv kasallik bo'lib, bemorlarning 73 foizi davolanishga javob bermaydi yoki takrorlanadi.
Boshqa tomondan, Breyanzi birlamchi markaziy asab tizimining lenfomasi bo'lgan bemorlarga tavsiya etilmaydi, garchi bu potentsial davolovchi davo hisoblanadi.
Bundan tashqari: Xitoyda CAR T-Cell terapiyasi
Breyanzi, a CAR T hujayra terapiyasi, will be very important in clinical practice, giving people with relapsed or refractory large B-cell lymphoma the chance for a long-lasting response with a personalized treatment experience, said Samit Hirawat, chief medical officer at Bristol Myers Squibb. Our unwavering commitment to advancing cell therapy research, providing breakthrough medicines, and supporting patients at every step of their treatment journey is reflected in the FDA approval.”
TRANSCEND NHL 73 tadqiqotida Breyanzi 54 foiz umumiy javob darajasi va 001 foiz to'liq javob (CR) darajasiga ega bo'lib, bu 3L+ LBCL da eng katta muhim sinov bo'lgan.
BMS’ immunoterapiya manufacturing plant in Bothell, Washington, will produce the novel cell treatment.
Hindistonda CAR T-Cell terapiyasi klinik sinovlar bosqichida va umid qilamanki, u tez orada tijorat maqsadlarida foydalanish uchun taqdim etiladi.
